O. H. Y. Yu

First name
O.
Last name
H. Y. Yu
Brunetti, V. C., St-Jean, A., Dell'Aniello, S., Fisher, A., H. Y. Yu, O., Bugden, S. C., et al. (2022). Characteristics of new users of recent antidiabetic drugs in Canada and the United Kingdom. Bmc Endocr Disord, 22, 241. http://doi.org/10.1186/s12902-022-01140-1
View
Cao, T. X. D., Filliter, C., Montastruc, F., H. Y. Yu, O., Fergusson, E., Rej, S., et al. (2022). Selective serotonin reuptake inhibitors and the risk of type 2 diabetes mellitus in youths. J Affect Disord, 318, 231-237. http://doi.org/10.1016/j.jad.2022.08.094
View
Pradhan, R., Yin, H., H. Y. Yu, O., & Azoulay, L. (2022). Incretin-Based Drugs and the Risk of Acute Liver Injury Among Patients With Type 2 Diabetes. Diabetes Care. http://doi.org/10.2337/dc22-0712
View
Brunetti, V. C., H. Y. Yu, O., Platt, R. W., & Filion, K. B. (2022). The Association of Long-Acting Insulin Analogue Use Versus Neutral Protamine Hagedorn Insulin Use With Major Adverse Cardiovascular Events Among Individuals With Type 2 Diabetes: A Population-Based Cohort Study. Diabetes Obes Metab. http://doi.org/10.1111/dom.14802
View
Lu, S., Yin, H., H. Y. Yu, O., & Azoulay, L. (2022). Incretin-Based Drugs and the Incidence of Prostate Cancer Among Patients with Type 2 Diabetes. Epidemiology. http://doi.org/10.1097/ede.0000000000001486
View
Chowdhury, R., Michaud, J., H. Y. Yu, O., Yin, H., Azoulay, L., & Renoux, C. (2022). Effectiveness and safety of apixaban vs. rivaroxaban in patients with atrial fibrillation and type 2 diabetes mellitus. Thromb Haemost. http://doi.org/10.1055/a-1798-2116
View
Pradhan, R., Patorno, E., Tesfaye, H., Schneeweiss, S., Yin, H., Franklin, J., et al. (2022). Glucagon-Like Peptide-1 Receptor Agonists and Risk of Anaphylactic Reaction Among Patients With Type 2 Diabetes: Multisite Population-Based Cohort Study. Am J Epidemiol. http://doi.org/10.1093/aje/kwac021
View
Douros, A., Yin, H., H. Y. Yu, O., Filion, K. B., Azoulay, L., & Suissa, S. (2017). Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events. Diabetes Care. http://doi.org/10.2337/dc17-0595
View
Douros, A., Abrahami, D., Yin, H., H. Y. Yu, O., Renoux, C., Hudson, M., & Azoulay, L. (2018). Use of Dipeptidyl Peptidase-4 Inhibitors and New-onset Rheumatoid Arthritis in Patients with Type 2 Diabetes. Epidemiology. http://doi.org/10.1097/ede.0000000000000891
View
Douros, A., Dell'Aniello, S., H. Y. Yu, O., Filion, K. B., Azoulay, L., & Suissa, S. (2018). Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study. Bmj. http://doi.org/10.1136/bmj.k2693
View